InMed Pharmaceuticals Inc. (INM)

The immediate catalyst driving this name is the amended merger with Mentari Therapeutics, which has injected significant capital ($290M total, including a $200M private placement) to extend the cash runway into 2029. This financing event has stabilized the near-term outlook, preventing a collapse, yet the stock remains trapped below its 50-day moving average, suggesting lingering skepticism among traders about the deal's final terms or execution. While the merger provides a necessary lifeline, the underlying business has been in a relentless freefall for seven consecutive years, erasing nearly 99.9% of its value since 2016. There is no dividend to provide income, and the company is burning through cash with negative operating flows. The recent price action shows a flat, range-bound pattern rather than a decisive breakout, indicating that while the merger offers a potential floor, the market has not yet priced in a robust recovery. Until the merger closes and delivers tangible pipeline progress, the investment case remains speculative rather than fundamental.